Chemistry, manufacturing, and controls (CMC) development of NCGC00413972 for preclinical safety evaluation and clinical trial
Active Awarded Last action
- Contract number
- 75N95023F00001
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $907,792
Award facts
- Opportunity
-
- 75N95023R00059 Solicitation number
- Contract value 100% obligated
- $907,791.77 Current and potential, with all options
- Completion date 67% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Albany, NY 12203, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $82,604 | |
| Exercise an Option | $280,124 | |
| Original award | $545,063 |
About this award
This federal contract award is for "CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) DEVELOPMENT OF NCGC00413972 FOR PRECLINICAL SAFETY EVALUATION AND CLINICAL TRIAL" and was issued to Curia Global Inc., doing business as Amri. The contract, valued at $907,791.77, is a delivery order under the "CRO Support for NCATS Drug Substance Development and Manufacture" indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), awarded this firm fixed-price contract. The contract involves the development of a drug candidate, including medicinal chemistry, chemical development, analytical testing, and good manufacturing practices (GMP) production. Curia has significant experience supporting various NIH institutes through prime and subcontract awards for pharmaceutical research and development services. No set-aside designation was used for this award.
Quick answers
Who was awarded contract 75N95023F00001?
75N95023F00001 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2023.
How much is contract 75N95023F00001 worth?
The government has obligated $907,792 on 75N95023F00001.
Which agency awarded contract 75N95023F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95023F00001 an order under another contract?
Yes. 75N95023F00001 is a delivery order under HHSN271201700005I, an indefinite delivery contract, on CRO Support for NCATS Drug Substance Development and Manufacture.
Was contract 75N95023F00001 competed?
The extent of competition for 75N95023F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award